The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vera Therapeutics, Inc. (“Vera” or “the Company”) (NASDAQ: VERA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Vera announced on January 3, 2023, what it called "positive topline results" in its Phase 2b ORIGIN clinical trial of its drug candidate atacicept. Despite the positive results, the Company would need to replicate the findings in a pivotal trial to receive regulatory approval. After analysts downgraded the Company’s stock, shares of Vera fell by almost 65% on January 4, 2023.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005875/en/